159 related articles for article (PubMed ID: 19040181)
1. Formulating a sulfonated antiviral dendrimer in a vaginal microbicidal gel having dual mechanisms of action.
Mumper RJ; Bell MA; Worthen DR; Cone RA; Lewis GR; Paull JR; Moench TR
Drug Dev Ind Pharm; 2009 May; 35(5):515-24. PubMed ID: 19040181
[TBL] [Abstract][Full Text] [Related]
2. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model.
Patton DL; Cosgrove Sweeney YT; McCarthy TD; Hillier SL
Antimicrob Agents Chemother; 2006 May; 50(5):1696-700. PubMed ID: 16641437
[TBL] [Abstract][Full Text] [Related]
3. SPL7013 Gel (VivaGel®) retains potent HIV-1 and HSV-2 inhibitory activity following vaginal administration in humans.
Price CF; Tyssen D; Sonza S; Davie A; Evans S; Lewis GR; Xia S; Spelman T; Hodsman P; Moench TR; Humberstone A; Paull JR; Tachedjian G
PLoS One; 2011; 6(9):e24095. PubMed ID: 21935377
[TBL] [Abstract][Full Text] [Related]
4. Virucidal activity of the dendrimer microbicide SPL7013 against HIV-1.
Telwatte S; Moore K; Johnson A; Tyssen D; Sterjovski J; Aldunate M; Gorry PR; Ramsland PA; Lewis GR; Paull JR; Sonza S; Tachedjian G
Antiviral Res; 2011 Jun; 90(3):195-9. PubMed ID: 21459115
[TBL] [Abstract][Full Text] [Related]
5. VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection.
Rupp R; Rosenthal SL; Stanberry LR
Int J Nanomedicine; 2007; 2(4):561-6. PubMed ID: 18203424
[TBL] [Abstract][Full Text] [Related]
6. Effect of buffers on the properties of microbicidal hydrogels containing monoglyceride as the active ingredient.
Kristmundsdóttir T; Sigurdsson P; Thormar H
Drug Dev Ind Pharm; 2003 Feb; 29(2):121-9. PubMed ID: 12648008
[TBL] [Abstract][Full Text] [Related]
7. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89.6P in macaques.
Jiang YH; Emau P; Cairns JS; Flanary L; Morton WR; McCarthy TD; Tsai CC
AIDS Res Hum Retroviruses; 2005 Mar; 21(3):207-13. PubMed ID: 15795526
[TBL] [Abstract][Full Text] [Related]
8. Structure activity relationship of dendrimer microbicides with dual action antiviral activity.
Tyssen D; Henderson SA; Johnson A; Sterjovski J; Moore K; La J; Zanin M; Sonza S; Karellas P; Giannis MP; Krippner G; Wesselingh S; McCarthy T; Gorry PR; Ramsland PA; Cone R; Paull JR; Lewis GR; Tachedjian G
PLoS One; 2010 Aug; 5(8):e12309. PubMed ID: 20808791
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004).
McGowan I; Gomez K; Bruder K; Febo I; Chen BA; Richardson BA; Husnik M; Livant E; Price C; Jacobson C;
AIDS; 2011 May; 25(8):1057-64. PubMed ID: 21505316
[TBL] [Abstract][Full Text] [Related]
10. Topical Astodrimer Sodium, a Non-Toxic Polyanionic Dendrimer, Demonstrates Antiviral Activity in an Experimental Ocular Adenovirus Infection Model.
Romanowski EG; Yates KA; Paull JRA; Heery GP; Shanks RMQ
Molecules; 2021 Jun; 26(11):. PubMed ID: 34198721
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of dendrimer SPL7013, a lead microbicide candidate against herpes simplex viruses.
Gong E; Matthews B; McCarthy T; Chu J; Holan G; Raff J; Sacks S
Antiviral Res; 2005 Dec; 68(3):139-46. PubMed ID: 16219368
[TBL] [Abstract][Full Text] [Related]
12. Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): a dose ranging, phase I study.
O'Loughlin J; Millwood IY; McDonald HM; Price CF; Kaldor JM; Paull JR
Sex Transm Dis; 2010 Feb; 37(2):100-4. PubMed ID: 19823111
[TBL] [Abstract][Full Text] [Related]
13. Effect of carrageenan on poloxamer-based in situ gel for vaginal use: Improved in vitro and in vivo sustained-release properties.
Liu Y; Zhu YY; Wei G; Lu WY
Eur J Pharm Sci; 2009 Jun; 37(3-4):306-12. PubMed ID: 19491020
[TBL] [Abstract][Full Text] [Related]
14. Evaluations of unformulated and formulated dendrimer-based microbicide candidates in mouse and guinea pig models of genital herpes.
Bernstein DI; Stanberry LR; Sacks S; Ayisi NK; Gong YH; Ireland J; Mumper RJ; Holan G; Matthews B; McCarthy T; Bourne N
Antimicrob Agents Chemother; 2003 Dec; 47(12):3784-8. PubMed ID: 14638483
[TBL] [Abstract][Full Text] [Related]
15. A randomized controlled trial of the safety of candidate microbicide SPL7013 gel when applied to the penis.
Chen MY; Millwood IY; Wand H; Poynten M; Law M; Kaldor JM; Wesselingh S; Price CF; Clark LJ; Paull JR; Fairley CK
J Acquir Immune Defic Syndr; 2009 Apr; 50(4):375-80. PubMed ID: 19214122
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of BufferGel, a novel vaginal microbicide, in women in the United States.
Mayer KH; Peipert J; Fleming T; Fullem A; Moench T; Cu-Uvin S; Bentley M; Chesney M; Rosenberg Z
Clin Infect Dis; 2001 Feb; 32(3):476-82. PubMed ID: 11170957
[TBL] [Abstract][Full Text] [Related]
17. Development of indomethacin Carbopol ETD 2001 gels and the influence of storage time and temperature on their stability.
Shawesh AM; Kaukonen A; Kallioinen S; Antikainen O; Yliruusi J
Pharmazie; 2003 Feb; 58(2):130-5. PubMed ID: 12641331
[TBL] [Abstract][Full Text] [Related]
18. In vitro studies on the influence of carbomers on the availability and acceptability of estradiol gels.
Amsellem E; Derrien F; Lanquetin M; Paris J; Marty JP
Arzneimittelforschung; 1998 May; 48(5):492-6. PubMed ID: 9638317
[TBL] [Abstract][Full Text] [Related]
19. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.
Chavoustie SE; Carter BA; Waldbaum AS; Donders GGG; Peters KH; Schwebke JR; Paull JRA; Price CF; Castellarnau A; McCloud P; Kinghorn GR
Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():13-18. PubMed ID: 31812702
[TBL] [Abstract][Full Text] [Related]
20. Temperature and pH sensitive hydrogels: an approach towards smart semen-triggered vaginal microbicidal vehicles.
Gupta KM; Barnes SR; Tangaro RA; Roberts MC; Owen DH; Katz DF; Kiser PF
J Pharm Sci; 2007 Mar; 96(3):670-81. PubMed ID: 17154368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
